FDA Seeks Clarity On DPP-4 Class Safety Signals With Linagliptin Post-Market Requirements
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is using the post-marketing study requirements for Boehringer Ingelheim GmbH's Tradjenta (linagliptin) to investigate some of the emerging safety concerns about the DPP-4 inhibitor class.
You may also be interested in...
Alogliptin Rejection Dents Takeda’s Diabetes Franchise
Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.
Review Of Reviews: Drug Review Profiles Of 2011
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.
BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence
Boehringer Ingelheim GmbH saw an opportunity to gather more and better head-to-head data for anti-diabetic Tradjenta in its post-market cardiovascular outcomes trial, but FDA couldn't picture a better comparator than gold-standard placebo.